In a report released today, Gaurav Goparaju from Berenberg Bank maintained a Buy rating on AbCellera Biologics (ABCL – Research Report), with a price target of $34.00. The company’s shares closed yesterday at $6.97.
Goparaju covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Ginkgo Bioworks Holdings, and Certara. According to TipRanks, Goparaju has an average return of -5.1% and a 39.76% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AbCellera Biologics with a $27.75 average price target.
See today’s best-performing stocks on TipRanks >>
ABCL market cap is currently $2.1B and has a P/E ratio of -37.90.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ABCL in relation to earlier this year. Most recently, in May 2023, Hansen Carl L. G., the CEO of ABCL bought 56,125.00 shares for a total of $151,537.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AbCellera Biologics Inc is a biotechnology company. The company develops antibodies to treat highly infectious diseases and various other types of diseases.
Read More on ABCL:
